Pancreatic Cancer Research

ResearcherAarhus UniversityActive in the last 2 years

Frank Viborg Mortensen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7580-8037; OpenAlex author ID A5022474555. Sources: OpenAlex.

Their work

Papers
28 (first author 9, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 7 papers · 2020: 5 papers · 2021: 1 paper · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers · 2025: 2 papers · 2026: 1 paper

Papers 28

  1. Circulating tumour DNA as a prognostic tool for surgically treated pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2025.106024↗
  2. Preoperative EUS-guided biopsy does not affect survival in patients with pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1097/eus.0000000000000156↗
  3. Performance of Different Comorbidity Indices in Predicting Mortality in Danish Pancreatic Cancer Patients. Co-author DOI 10.2147/clep.s560098↗
  4. Beta-blocker use and survival after pancreatic cancer surgery: A nationwide population-based cohort study. Last author DOI 10.1002/pds.5726↗
  5. Effect of adjuvant chemotherapy after pancreatectomy in patients with node-negative pancreatic cancer: target trial emulation. Last author DOI 10.1093/bjs/znad398↗
  6. Effect of surgery versus chemotherapy in pancreatic cancer patients: a target trial emulation. Last author DOI 10.1093/jnci/djae024↗
  7. Impact on Survival of Early Versus Late Initiation of Adjuvant Chemotherapy After Pancreatic Adenocarcinoma Surgery: A Target Trial Emulation. Last author DOI 10.1245/s10434-023-14497-x↗
  8. Impact of prior cancer diagnosis on pancreatic cancer outcomes: A Danish Nationwide, population-based Cohort study. First author DOI 10.1016/j.canep.2023.102452↗
  9. Real-Time Identification of Pancreatic Cancer Cases Using Artificial Intelligence Developed on Danish Nationwide Registry Data. First author DOI 10.1200/cci.23.00084↗
  10. Trends in pancreatic cancer incidence, characteristics, and outcomes in Denmark 1980-2019: A nationwide cohort study. Last author DOI 10.1016/j.canep.2022.102230↗
  11. Disparity in use of modern combination chemotherapy associated with facility type influences survival of 2655 patients with advanced pancreatic cancer. Co-author DOI 10.1080/0284186x.2021.2012252↗
  12. Intra-observer agreements in multidisciplinary team assessments of pancreatic cancer patients. Last author DOI 10.1002/jso.26670↗
  13. Statins and pancreatic cancer risk in patients with chronic pancreatitis: A Danish nationwide population-based cohort study. Co-author DOI 10.1002/ijc.32264↗
  14. Acute pancreatitis as an early marker of pancreatic cancer and cancer stage, treatment, and prognosis. Last author DOI 10.1016/j.canep.2019.101647↗
  15. Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. Co-author DOI 10.1016/j.ejca.2020.01.015↗
  16. Predictors of underlying pancreatic cancer in patients with acute pancreatitis: a Danish nationwide cohort study. First author DOI 10.1016/j.hpb.2019.08.013↗
  17. Reply to Liu et al., "Study of underlying pancreatic cancer could be improved". First author DOI 10.1016/j.hpb.2020.05.004↗
  18. Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation. Last author DOI 10.1002/bjs.11093↗
  19. Author response to: It is time for a biological definition of locally advanced pancreatic cancer. First author DOI 10.1002/bjs.11250↗
  20. Author's Reply to: "Design flaws in statins and pancreatic cancer research" (IJC-19-0941). Co-author DOI 10.1002/ijc.32349↗
  21. Waiting time to surgery and pancreatic cancer survival: A nationwide population-based cohort study. First author DOI 10.1016/j.ejso.2019.05.029↗
  22. Antihypertensive drugs and pancreatic cancer risk in patients with chronic pancreatitis: a Danish nationwide population-based cohort study. First author DOI 10.1038/s41416-019-0562-y↗
  23. The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Co-author DOI 10.1080/0284186x.2019.1581374↗
  24. Comment on "Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer". First author DOI 10.1097/sla.0000000000003422↗
  25. Acute Pancreatitis and Pancreatic Cancer Risk: A Nationwide Matched-Cohort Study in Denmark. Last author DOI 10.1053/j.gastro.2018.02.011↗
  26. Urban versus rural residency and pancreatic cancer survival: A Danish nationwide population-based cohort study. Last author DOI 10.1371/journal.pone.0202486↗
  27. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. First author DOI 10.1038/ajg.2017.218↗
  28. Pancreatic cancer survival in central and northern Denmark from 1998 through 2009: a population-based cohort study. Co-author DOI 10.2147/clep.s20611↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jakob Kirkegård · 24 shared papers, 2017–2025 · strength 4.63
  2. Deirdre P Cronin-Fenton · 12 shared papers, 2011–2024 · strength 1.88
  3. Claus Wilki Fristrup · 10 shared papers, 2018–2026 · strength 1.45
  4. Morten Bækbo Ladekarl · 7 shared papers, 2018–2024 · strength 1.15
  5. Uffe Heide‐Jørgensen · 6 shared papers, 2018–2025 · strength 1.13
  6. Michael Bau Mortensen · 7 shared papers, 2019–2026 · strength 0.97
  7. Sönke Detlefsen · 4 shared papers, 2019–2026 · strength 0.68
  8. Jennifer Leigh Lund · 4 shared papers, 2019–2024 · strength 0.66
  9. Carsten Palnæs Hansen · 5 shared papers, 2018–2025 · strength 0.64
  10. Per Pfeiffer · 4 shared papers, 2019–2026 · strength 0.56
  11. Anders Bo Bojesen · 2 shared papers, 2022–2023 · strength 0.53
  12. Charles E. Gaber · 2 shared papers, 2020–2024 · strength 0.36
  13. Louise S. Rasmussen · 3 shared papers, 2019–2022 · strength 0.31
  14. Nickolai Malte Kristensen · 1 shared paper, 2023 · strength 0.31
  15. Peter Vilmann · 1 shared paper, 2025 · strength 0.26
  16. Mogens Tornby Stender · 1 shared paper, 2025 · strength 0.26
  17. Bojan Kovacevic · 1 shared paper, 2025 · strength 0.26
  18. Carlos Fernández Moro · 1 shared paper, 2026 · strength 0.25
  19. Trine Aaquist · 1 shared paper, 2026 · strength 0.25
  20. Ernesto Sparrelid · 1 shared paper, 2026 · strength 0.25
  21. Jorg H. Kleeff · 1 shared paper, 2026 · strength 0.25
  22. Karin de Stricker · 1 shared paper, 2026 · strength 0.25
  23. Britta Weber · 2 shared papers, 2020–2022 · strength 0.23
  24. Svein Olav Bratlie · 2 shared papers, 2019–2021 · strength 0.18
  25. Stephen J. Wigmore · 2 shared papers, 2019–2021 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.